These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 19200624)

  • 1. Design of novel aminopyrrolidine factor Xa inhibitors from a screening hit.
    Zbinden KG; Anselm L; Banner DW; Benz J; Blasco F; Décoret G; Himber J; Kuhn B; Panday N; Ricklin F; Risch P; Schlatter D; Stahl M; Thomi S; Unger R; Haap W
    Eur J Med Chem; 2009 Jul; 44(7):2787-95. PubMed ID: 19200624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure- and property-based design of factor Xa inhibitors: pyrrolidin-2-ones with acyclic alanyl amides as P4 motifs.
    Young RJ; Campbell M; Borthwick AD; Brown D; Burns-Kurtis CL; Chan C; Convery MA; Crowe MC; Dayal S; Diallo H; Kelly HA; King NP; Kleanthous S; Mason AM; Mordaunt JE; Patel C; Pateman AJ; Senger S; Shah GP; Smith PW; Watson NS; Weston HE; Zhou P
    Bioorg Med Chem Lett; 2006 Dec; 16(23):5953-7. PubMed ID: 16982190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of the terminal P4 domain in a series of D-phenylglycinamide-based factor Xa inhibitors.
    Franciskovich JB; Masters JJ; Weber WW; Klimkowski VJ; Chouinard M; Sipes PR; Johnson LM; Snyder DW; Chastain MK; Craft TJ; Towner RD; Gifford-Moore DS; Froelich LL; Smallwood JK; Foster RS; Smith GF; Liebeschuetz JW; Murray CW; Young SC
    Bioorg Med Chem Lett; 2007 Dec; 17(24):6910-3. PubMed ID: 17976987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arylsulfonamides: a study of the relationship between activity and conformational preferences for a series of factor Xa inhibitors.
    Senger S; Convery MA; Chan C; Watson NS
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5731-5. PubMed ID: 16982192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anthranilamide inhibitors of factor Xa.
    Mendel D; Marquart AL; Joseph S; Waid P; Yee YK; Tebbe AL; Ratz AM; Herron DK; Goodson T; Masters JJ; Franciskovich JB; Tinsley JM; Wiley MR; Weir LC; Kyle JA; Klimkowski VJ; Smith GF; Towner RD; Froelich LL; Buben J; Craft TJ
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4832-6. PubMed ID: 17624775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformational conversion of antithrombin to a fully activated substrate of factor Xa without need for heparin.
    Huntington JA; Gettins PG
    Biochemistry; 1998 Mar; 37(10):3272-7. PubMed ID: 9521646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the active site of human factor Xa protein by NMR screening of small molecule probes.
    Fielding L; Fletcher D; Rutherford S; Kaur J; Mestres J
    Org Biomol Chem; 2003 Dec; 1(23):4235-41. PubMed ID: 14685325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based drug design of pyrrolidine-1, 2-dicarboxamides as a novel series of orally bioavailable factor Xa inhibitors.
    Van Huis CA; Bigge CF; Casimiro-Garcia A; Cody WL; Dudley DA; Filipski KJ; Heemstra RJ; Kohrt JT; Narasimhan LS; Schaum RP; Zhang E; Bryant JW; Haarer S; Janiczek N; Leadley RJ; McClanahan T; Thomas Peterson J; Welch KM; Edmunds JJ
    Chem Biol Drug Des; 2007 Jun; 69(6):444-50. PubMed ID: 17581239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Halothiophene benzimidazoles as P1 surrogates of inhibitors of blood coagulation factor Xa.
    Mederski WW; Dorsch D; Anzali S; Gleitz J; Cezanne B; Tsaklakidis C
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3763-9. PubMed ID: 15203158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and evaluation of acylguanidine FXa inhibitors.
    O'Connor SP; Atwal K; Li C; Liu EC; Seiler SM; Shi M; Shi Y; Stein PD; Wang Y
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4696-9. PubMed ID: 18644722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereoselective synthesis and biological evaluation of 3,4-diaminocyclohexanecarboxylic acid derivatives as factor Xa inhibitors.
    Nagata T; Nagamochi M; Kobayashi S; Komoriya S; Yoshino T; Kanno H
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4587-92. PubMed ID: 18675545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achieving structural diversity using the perpendicular conformation of alpha-substituted phenylcyclopropanes to mimic the bioactive conformation of ortho-substituted biphenyl P4 moieties: discovery of novel, highly potent inhibitors of Factor Xa.
    Qiao JX; Cheney DL; Alexander RS; Smallwood AM; King SR; He K; Rendina AR; Luettgen JM; Knabb RM; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4118-23. PubMed ID: 18550370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (R)-3-Amidinophenylalanine-derived inhibitors of factor Xa with a novel active-site binding mode.
    Mueller MM; Sperl S; Stürzebecher J; Bode W; Moroder L
    Biol Chem; 2002; 383(7-8):1185-91. PubMed ID: 12437104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation of 1-(4-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective and bioavailable inhibitors of coagulation factor Xa.
    Fevig JM; Cacciola J; Buriak J; Rossi KA; Knabb RM; Luettgen JM; Wong PC; Bai SA; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3755-60. PubMed ID: 16682200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure-activity relationship and X-ray crystallography.
    Nazaré M; Will DW; Matter H; Schreuder H; Ritter K; Urmann M; Essrich M; Bauer A; Wagner M; Czech J; Lorenz M; Laux V; Wehner V
    J Med Chem; 2005 Jul; 48(14):4511-25. PubMed ID: 15999990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 2: A survey of P4 motifs.
    Jia ZJ; Wu Y; Huang W; Zhang P; Clizbe LA; Goldman EA; Sinha U; Arfsten AE; Edwards ST; Alphonso M; Hutchaleelaha A; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2004 Mar; 14(5):1221-7. PubMed ID: 14980670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of cation-pi interactions in protein-ligand complexes: crystal-structure analysis of Factor Xa bound to a quaternary ammonium ion ligand.
    Schärer K; Morgenthaler M; Paulini R; Obst-Sander U; Banner DW; Schlatter D; Benz J; Stihle M; Diederich F
    Angew Chem Int Ed Engl; 2005 Jul; 44(28):4400-4. PubMed ID: 15952226
    [No Abstract]   [Full Text] [Related]  

  • 18. SAR and factor IXa crystal structure of a dual inhibitor of factors IXa and Xa.
    Smallheer JM; Alexander RS; Wang J; Wang S; Nakajima S; Rossi KA; Smallwood A; Barbera F; Burdick D; Luettgen JM; Knabb RM; Wexler RR; Jadhav PK
    Bioorg Med Chem Lett; 2004 Nov; 14(21):5263-7. PubMed ID: 15454208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computer-aided design of a factor Xa inhibitor by using MCSS functionality maps and a CAVEAT linker search.
    Takano Y; Koizumi M; Takarada R; Kamimura MT; Czerminski R; Koike T
    J Mol Graph Model; 2003 Nov; 22(2):105-14. PubMed ID: 12932781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parallel synthesis and structure-activity relationships of a series of highly potent, selective, and neutral factor Xa inhibitors.
    Bauer SM; Goldman EA; Huang W; Su T; Wang L; Woolfrey J; Wu Y; Zuckett JF; Arfsten A; Huang B; Kothule J; Lin J; May B; Sinha U; Wong PW; Hutchaleelaha A; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2004 Aug; 14(15):4045-50. PubMed ID: 15225723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.